CN Patent

CN113880809B — 一种嘧啶类衍生物及其制备方法和应用

Assigned to Shengshi Taike Biopharmaceutical Technology Suzhou Co ltd · Expires 2022-10-18 · 4y expired

What this patent protects

本发明实施例涉及一种嘧啶类衍生物及其制备方法和应用，所述嘧啶类衍生物选自：通式(I)所示的化合物或其互变异构体、对映异构体、非对映异构体、内消旋体、外消旋体或其混合物形式，或其可药用盐或其前体药物。该嘧啶类衍生物表现出优异的抑制CDK的效果和作用。

USPTO Abstract

本发明实施例涉及一种嘧啶类衍生物及其制备方法和应用，所述嘧啶类衍生物选自：通式(I)所示的化合物或其互变异构体、对映异构体、非对映异构体、内消旋体、外消旋体或其混合物形式，或其可药用盐或其前体药物。该嘧啶类衍生物表现出优异的抑制CDK的效果和作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN113880809B
Jurisdiction
CN
Classification
—
Expires
2022-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Shengshi Taike Biopharmaceutical Technology Suzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.